|Institutional Source||Beutler Lab|
|Gene Name||angiopoietin-like 4|
|Synonyms||FIAF, BK89, NG27, HFARP|
|Essential gene?||Non essential (E-score: 0.000)|
|Stock #||R3881 (G1)|
|Chromosomal Location||33773750-33781575 bp(-) (GRCm38)|
|Type of Mutation||missense|
|DNA Base Change (assembly)||G to A at 33777034 bp (GRCm38)|
|Amino Acid Change||Proline to Serine at position 323 (P323S)|
|Ref Sequence||ENSEMBL: ENSMUSP00000002360 (fasta)|
|Gene Model||predicted gene model for transcript(s): [ENSMUST00000002360] [ENSMUST00000173869]|
AA Change: P323S
PolyPhen 2 Score 0.541 (Sensitivity: 0.88; Specificity: 0.91)
AA Change: P323S
|Meta Mutation Damage Score||0.0948|
|Coding Region Coverage||
FUNCTION: [Summary is not available for the mouse gene. This summary is for the human ortholog.] This gene encodes a glycosylated, secreted protein containing a C-terminal fibrinogen domain. The encoded protein is induced by peroxisome proliferation activators and functions as a serum hormone that regulates glucose homeostasis, lipid metabolism, and insulin sensitivity. This protein can also act as an apoptosis survival factor for vascular endothelial cells and can prevent metastasis by inhibiting vascular growth and tumor cell invasion. The C-terminal domain may be proteolytically-cleaved from the full-length secreted protein. Decreased expression of this gene has been associated with type 2 diabetes. Alternative splicing results in multiple transcript variants. This gene was previously referred to as ANGPTL2 but has been renamed ANGPTL4. [provided by RefSeq, Sep 2013]
PHENOTYPE: Mice homozygous for disruptions in this gene display decreased levels of triglycerides and cholesterol and a lower increase in body fat after exposure to gut microbiota. [provided by MGI curators]
|Allele List at MGI|
|Other mutations in this stock||
|Other mutations in Angptl4||
(F):5'- TGTAGCTCTGTGCCAGAATG -3'
(R):5'- TGCACAGCATCACAGGGAAC -3'
(F):5'- TTCAATGACTGGCCCATAGG -3'
(R):5'- ACCGAGGAAGCCAATTGG -3'